Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 5;7(3):207-212.
doi: 10.14744/bej.2022.46794. eCollection 2022.

Comparison of Ranibizumab Treatment Response of Superior and Inferior Temporal Branch Retinal Vein Occlusion: A Year Follow-Up

Esra Turkseven Kumral  1 , Nursal Melda Yenerel  1 , Nimet Yesim Ercalik  1 , Levent Karabas  2
Affiliations

Comparison of Ranibizumab Treatment Response of Superior and Inferior Temporal Branch Retinal Vein Occlusion: A Year Follow-Up

Esra Turkseven Kumral et al. Beyoglu Eye J. .

Abstract

Objectives: The aim of the study was to compare ranibizumab treatment response of macular edema secondary to superior and inferior temporal branch retinal vein occlusion.

Methods: Sixty-four eyes of 64 patients treated with 0.5 mg/0.05 mL ranibizumab due to macular edema secondary to branch retinal vein occlusion were enrolled in this retrospective study. Thirty-eight eyes with superior temporal branch retinal vein occlusion were classified as Group 1 and 26 eyes with inferior temporal branch retinal vein occlusion as Group 2. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and the number of intravitreal injections were evaluated and compared between the groups.

Results: The mean baseline, 3rd, 6th, 9th, and 12th month BCVA values in Group 1 were 0.77±0.47, 0.37±0.20, 0.37±0.22, 0.38±0.24, and 0.35±0.18 logarithm of the minimum angle of resolution (logMAR) and in Group 2 were 0.75±0.45, 0.37±0.18, 0.35±0.19, 0.32±0.17, and 0.28±0.20 logMAR, respectively. The mean baseline, 3rd, 6th, 9th, and 12th month CMT values in Group 1 were 522.92±136.01, 318.03±66.65, 287.53±48.27, 271.95±32.47, and 280.47±91.66 µm and in Group 2 were 524.08±145.51, 289.85±53.08, 268.96±31.57, 260.77±30.22, and 244.04±44.78 µm, respectively. BCVA and CMT improved significantly within both groups after the treatment (p<0.05) and there was no statistically significant difference between the groups (p>0.05). However, a significantly higher number of injections was needed for Group 1.

Conclusion: Ranibizumab improved the visual and anatomical outcomes similarly in both superior and inferior temporal branch retinal vein occlusion with macular edema. However, more frequent injections were needed to achieve the same efficacy in superior temporal branch retinal vein occlusion.

Keywords: Branch retinal vein occlusion; central macular thickness; injection frequency; ranibizumab; visual acuity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
The mean Best-corrected visual acuity values at each time points.
Figure 2
Figure 2
The mean Central macular thickness values at each time points.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Parodi MB, Bandello F. Branch retinal vein occlusion:Classification and treatment. Ophthalmologica. 2009;223:298–305. - PubMed
    1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion:The beaver dam eye study. Arch Ophthalmol. 2008;126:513–8. - PubMed
    1. Feist RM, Ticho BH, Shapiro MJ, Farber M. Branch retinal vein occlusion and quadrantic variation in arteriovenous crossings. Am J Ophthalmol. 1992;113:664–8. - PubMed
    1. Wong TY, Scott IU. Clinical practice. Retinal vein occlusion. N Engl J Med. 2010;363:2135–44. - PubMed
    1. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247:147–63. - PubMed

LinkOut - more resources